Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPI Effect on Colonic Microbiome in Children
NCT02016820Terminated
- Sponsor
- Columbia University
- Start
- Nov 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of omeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Columbia University. Primary endpoint: Change in Fecal Microbiome Diversity at 8 weeks. Started Nov 2014; status: terminated.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02016820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016820.